Skip to main content

Crispr Therapeutics AG Value Stock - Dividend - Research Selection

Crispr therapeutics

ISIN: CH0334081137 , WKN: A2AT0Z

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle

Crispr Therapeutics secures approval for gene editing therapy, but faces patent battle. CRSP is likely to remain volatile. Read more on CRSP stock here.

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

These two stocks could have vastly different long-term performances.

Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today

CRISPR Therapeutics AG (CRSP) closed at $55.56 in the latest trading session, marking a +0.96% move from the prior day.

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Vertex's stock has risen 18% since last December, matching the SPY index. See why I recommend buying VRTX stock due to its robust cystic fibrosis revenue.

Crispr Therapeutics: Beaten Down But Not Broken


3 Top-Rated Gene Editing Stocks Actually Making Money

Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9. It is the most accurate, quickest and least expensive method. Developments in the gene editing space have led to valuable stocks with strong ratings emerging that are worthy of investment. However, not all of these companies are profitable. In fact, the majority are not. Most of the gene edit

Is CRISPR Therapeutics AG (CRSP) the Best Stock to Buy and Hold for 5 Years?

We recently compiled a list of the 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other stocks. As the saying goes, time and tide wait for nobody. This also holds […]

Nike and Alphabet downgraded: Wall Street's top analyst calls

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Crispr Therapeutics assumed with a Neutral at Guggenheim

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.

With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That’s because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time. It changes the base instructions of the human body for how the body is maintained and protected. As a result, several h